chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arm was swollen, painful, red, itchy including palms with patient reporting low fevers that lasted up to six days after the vaccination on 6/20/2023. The patient reports that the swelling, redness and pain are resolving as of 6/26/2023.
Was see on November 11 for right axilla lump. Pain and numbness down arm.
Within 12 hrs: full body aches, full body chills, very low energy. For 36 hrs after: extremely low energy (stayed in bed when normally I go running & am very active). Still totally manageable symptoms, & preferable to covid. But have not had reactions to any vaccines previously, was surprised.  Also believe these are in common symptoms/signs for vaccine. Just adding data.
February 4 I began breaking out with Herpes  And developed pain in left buttock and thigh
Information has been received from a health department registered nurse who received information from the patient's mother concerning a 7 year old male with no pertinent medical history and no drug reactions/ allergies who on 16-NOV-2001 was vaccinated subcutaneous in right arm with a first dose of VARIVAX (lot# 638245/0779L). There was no concomitant medication. On 17-MAR-2008 the patient developed chickenpox. The patient was evaluated by an unspecified physician and no treatment was prescribed. No specific symptoms or treatment was reported. Unspecified medical attention was sought with an office visit. The product quality complaint unit was not involved. This is one of several reports that was received from the same source. Additional information is not expected.
This is a spontaneous report from a contactable consumer, the patient. A 69-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 13Apr2021 at 14:30 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, coronary heart disease, lactose intolerant, IBD. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient took other medication in two weeks, but unspecified. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 22Mar2021 at 15:15 as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 the patient experienced tinnitus - ringing in both ears with high pitch which prolonged for 24 hours per day/ 7 days per week. No therapeutic measures were taken as a result of the event tinnitus. The clinical outcome of the event tinnitus was not resolved, at the time of this report.
Pt had 2x3 cm erythema without warmth, edema or tenderness.
heart palpitation for the last 20 minutes; difficulty in breathing; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (heart palpitation for the last 20 minutes) and DYSPNOEA (difficulty in breathing) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Sep-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Sep-2021, the patient experienced PALPITATIONS (heart palpitation for the last 20 minutes) and DYSPNOEA (difficulty in breathing). At the time of the report, PALPITATIONS (heart palpitation for the last 20 minutes) and DYSPNOEA (difficulty in breathing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported No treatment medications were reported
Red raised rash on left side of stomach - no itching. I noticed it while changing 2 1/2 days after getting the vaccine
The expired Jynneos vaccine was administered to the patient, intradermally; The expired Jynneos vaccine was administered to the patient, intradermally; Case reference number US-BN-2023-000054 is a spontaneous case report initially received from other health care professional via Communications (reference number: USBAV23-0061) on 11-Jan-2023 and concerns an adult patient of unknown gender.  The patient's medical history and concomitant medication details were not provided.  On 03-Jan-2023, the patient was vaccinated with the first dose of expired Jynneos vaccine (batch number: FDP00014; expiration date: 19-Dec-2022), at an unknown dose or site of administration, intradermally, for monkeypox (explicitly coded as 'expired vaccine used' and 'intradermal injection').    At the time of this report, it was unknown if the patient experienced any adverse event due to Jynneos.  Additional information received from Bavarian Nordic on 11-Jan-2023 included the local BN case ID.  This case is linked to cases US-BN-2023-000050, US-BN-2023-000051, US-BN-2023-000052, US-BN-2023-000054 and US-BN-2023-000055 (same reporter).; Reporter's Comments: An adult patient was vaccinated with the first dose of expired Jynneos vaccine intradermally. Intradermal injection and expired product administered are listed by convention. No associated adverse events have been reported. Intradermal injection and expired product administered have been considered not related to the suspect product. The case is non-serious.; Sender's Comments: An adult patient was vaccinated with the first dose of expired Jynneos vaccine intradermally. Intradermal injection and expired product administered are listed by convention. No associated adverse events have been reported. Intradermal injection and expired product administered have been considered not related to the suspect product. The case is non-serious.
I woke the night of the vaccine with dry heaves, dizziness and weakness and for the next two weeks suffered from a debilitating fatigue as well as daily headaches for almost a month.  I have been to the doctors for MRI  and other test to clarify if this was associated with my other diagnoses and it is not. (Fatigue can be debilitating with my MS but only with too much activity and this was ongoing since the day of the shot and constant rest. It usually takes only a few days rest for MS fatigue to Pass as of 2013 when I began Low Dose Naltrexone 3mg.)
Severe chills that lasted 20 min. On 01/10/2010 leg problem developed, not being able to lift leg(s) like before, pain in the tendon between leg and hip junction. As of 01/17/2010 no further symptoms.
later that night my mouth and gums swollen inside and active strong pain on my 2 wisdom teeth ,also pain on head and neck took a lot more advil then took loratadine 10mg took the whole weekend to feel better
IMMOBILITY AROUND ANKLES AND FEET; STIFFNESS; DIFFICULTY IN STANDING; JOINT PAIN; MUSCLE PAIN; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On APR-2021, the subject experienced immobility around ankles and feet. On APR-2021, the subject experienced stiffness. On APR-2021, the subject experienced difficulty in standing. On APR-2021, the subject experienced joint pain. On APR-2021, the subject experienced muscle pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from muscle pain, joint pain, stiffness, difficulty in standing, and immobility around ankles and feet. This report was non-serious.; Sender's Comments: V0: Medical assessment comment was not required as per standard procedure as case assessed as non-serious.
Hardly lift her left arm; asymptomatic after receiving extra erroneous dose of Bexero vaccine; This non-serious case was reported by a nurse via call center representative and described the occurrence of mobility decreased in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included Men B NVS (Bexsero) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Bexsero. On 23-OCT-2023, the patient received Bexsero (intramuscular). On 23-OCT-2023, not applicable after receiving Bexsero and an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: asymptomatic after receiving extra erroneous dose of Bexero vaccine). On an unknown date, the patient experienced mobility decreased (Verbatim: Hardly lift her left arm). The patient was treated with paracetamol (Tylenol) and ibuprofen (Advil). The outcome of the mobility decreased was resolved and the outcome of the extra dose administered was unknown.   It was unknown if the reporter considered the mobility decreased to be related to Bexsero and Bexsero Pre-Filled Syringe Device.     It was unknown if the company considered the mobility decreased to be related to Bexsero and Bexsero Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date 23 Oct 2023: The reporter consented to follow up. The HCP reported that patient could hardly lift her left arm 1 day after vaccination with 2nd dose of BEXSERO. The patient took Tylenol and Advil 12 hours afterwards the symptom resolved (within the day). The Patient was asymptomatic after receiving extra erroneous dose of Bexero vaccine, which led to extra dose administered. The reporter consented to follow up.
Patient received Moderna Covid-19 vaccine that underwent a temperature excursion; Patient received Moderna Covid-19 vaccine that underwent a temperature excursion; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014B22A, 023C21A and DA123A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 15-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jul-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jul-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received Moderna Covid-19 vaccine that underwent a temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that, the nurse had discovered 2 temperature excursions of the Moderna COVID-19 vaccine for two different lot numbers of the Moderna COVID-19 vaccine. The temperature in the refrigerator that the Moderna COVID-19 vaccine reached 13.1 degrees Celsius on 28-Jun-2022. On 19-Jul-2022, the vaccine reached a temperature of 9 degrees Celsius. Further nurse stated that, none of the vaccine in the refrigerator underwent two different temperature excursions.  Later, the patient received Moderna COVID-19 vaccine that underwent a temperature excursion. The temperature excursion was not known of at the time of administration of the vaccine. The temperature excursion was found out about after a review of the temperature datalogger on the refrigerator that the Moderna COVID-19 vaccine was stored in. The nurse had used the online temperature excursion tool and was comfortable that her patient's doses were valid and that the affected vaccine was viable for future doses.  It was unknown if patient had side effects after any dose.  No treatment medications were reported.   This case was linked to MOD-2022-612877 (Patient Link).
Patient reported diarrhea, headache, myalgias, chills, and fever 2 days after receiving Td vaccine. Was bedridden for four days. Continues to experience fatigue and cough as of 4/23/21.
About 12 hours after shot, severe chills lasting for a couple hours. No fever.  About 20 hours after shot, fatigue lasting throughout the day. No fever. About 32 hours after shot, first noticed face breaking out, like acne.  About 44 hours after shot, forehead severly broken out with red spots. Face not as bad.
Loud ringing in both ears started 2 days after the vaccination. Each ear has a different sound and pitch. Tinnitus has been persistent 24/7 since the onset.
LARGE (20 BY 20 CM.) ERYTHEMATOUS MASS AT INJECTION SITE SIX DAYS FOLLOWING INJECTION, NO TREATMENT BY INDIVIDUAL, I AM INFECITON PREVENTION: ON 1/6/2021 I VIEWED AND RECORDED THE ARM SWELLING, ADVISED OTC BENADRYL 25 MG WHEN NOT DRIVING AND IMMEDIATE APPLICATION OF A COLD COMPRESS. ON 1/7/2021 BY PHONE THE INDIVISDUAL STATED SHE WA SNOT ANY BETTER AND I REFERRED HER TO HER PHYSICIAN.
11 PM I started feeling fatigued, around 3AM woke up feeling feverish, high fever about 103.1, headache, took Tylenol, woke up on 12/23 around 8, fever spiked back up on 12/23 to 104.3 by afternoon. Took Tylenol every 4 hours. By midnight temp was about 99. Next day 12/24, still tired. Got itchy under my watch and rings. Took Benadryl. Faded away the following day. Contacted MD by text. MD recommended rash treatment with Benadryl & Hydrocortisone. Fever had broken by that point.
Janssen covid19 vaccine given to underage patient. Patient was 17 yrs and 11 months old when he received vaccine
3 year old given Moderna as 1st booster; Monovalent vaccine given as a booster dose; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (3 year old given Moderna as 1st booster), WRONG PRODUCT ADMINISTERED (Monovalent vaccine given as a booster dose) and NO ADVERSE EVENT (No adverse event) in a 3-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR9236B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer vaccines (1st dose, lot number FT9142) on 07-Jul-2022, Pfizer vaccines (2nd dose and lot number FT9142) on 21-Jul-2022. Past adverse reactions to the above products included No adverse event with Pfizer vaccines and Pfizer vaccines.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (3 year old given Moderna as 1st booster), WRONG PRODUCT ADMINISTERED (Monovalent vaccine given as a booster dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (3 year old given Moderna as 1st booster), WRONG PRODUCT ADMINISTERED (Monovalent vaccine given as a booster dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (3 year old given Moderna as 1st booster) and WRONG PRODUCT ADMINISTERED (Monovalent vaccine given as a booster dose).    The concomitant medication was not reported by reporter. It was reported that a staff at a pediatric clinic called to report that they inadvertently administered the Moderna Covid-19 vaccine (blue cap with pink border) to a 3 year old for their 1st booster dose. They wanted to know how to proceed and if they had to watch out for any adverse reactions on this patient.  No adverse reactions had been reported. The treatment medication was not reported by reporter.
arthralgias, myalgias, h/a, dizziness, photophobia;professional tennis player;bitten in buttock by woodchuck;26SEP95 f/u from MD tx elsewhere;suffered several arthralgias w/o findings save dec ROM of joints;now full has full pain free ROM;
Case number PHEH2013US009362 is an initial spontaneous report received from a consumer on 18 Apr 2013. This report refers to a female patient of an unknown age. Her medical history and concomitant medication were not reported. She was vaccinated with MENVEO, (batch number: unknown) on 12 Apr 2013 (Friday). On an unspecified date, injection site became red and was itchy. The outcome of the events was not reported. No other information was provided.
After 2days of vaccination, I started to cough. Then after one week, blood came out. I took a X-ray and CT scan and the CT specialist described I have LAM disease.  Currently I?m waiting to see lung specialist.
This case was reported by a pharmacy technician and described a subject (age and gender unknown) who did not respond to immunization to the Engerix-B immunization series. Past medical history,concurrent conditions and concurrent medications were unknown. On an unspecified date before 27 July 2006, the subject received a dose of Engerix-B. On an unspecified date after vaccination with Engerix-B, it was reported that the vaccine was "not effective." Further information was not reported.
Initial unsolicited report received from a nurse on 18-JUL-2017. This case involves a two-month-old female patient who was vaccinated with a first dose of PENTACEL a dose of PREVNAR (manufacturer: Wyeth) a dose of ROTAVAX (manufacturer: Merck) (for all the vaccines; batch number, expiry date, dose, dose in series, route and site of administration were not reported) on 17-JUL-2017 (also reported as 18-JUL-2017). Patient's medical history and concomitant medications were not reported. On 17-JUL-2017 (also reported as 18-JUL-2017), immediately following the vaccination, the patient became listless and lethargic. Lab data and corrective treatment were not reported. On 17-JUL-2017 (also reported as 18-JUL-2017), the patient recovered from the event (it was reported that 'this lasted 15 minutes and then patient began acting normally'). List of documents held by sender: none.
PATIENT RECEIVED A JOHNSON AND JOHNSON VACCINE BY PHARMACY ON 5/8/21. WHEN ENTERING INFORMATION INTO THE WEBSITE, WE NOTICED THAT THE PATIENT HAD ALREADY RECEIVED A PFIZER DOSE ON 3/6/21 FROM ANOTHER SITE. WHEN WE BROUGHT THIS UP TO THE PATIENT, HE DENIED EVER RECEIVING ANY OTHER VACCINE.
This spontaneous report received from a consumer concerned multiple patients. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. The drug was associated with Medication error. No concomitant medications were reported. On an unspecified date, the patient experienced issues with walking, recalled shot, and issues with arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the issues with walking, issues with arm and recalled shot was not reported. This report was non-serious. This report was associated with a product quality complaint: 90000247526. The suspected product quality complaint has been confirmed to be voided (did not meet PQC criteria, as this record describes a series of adverse reactions to the product subsequently administration. There was no product quality issue described and the case does not meet the definition for a product quality complaint (PQC) or explicitly allege a potency issue) based on the PQC evaluation/investigation performed. This case, from the same reporter is linked to 20220848257 and 20220846104.
Few minutes after 15 minute monitoring clearance, employee returned with itching on left lower back.  Upon examination, area reddened with bolder hives noted.  Vaccination at 1447, left area at 1502, returned to clinic at 1524.  Patient given 50 mg of oral Benadryl.  Within 15 min of medication, noted improvement, hives gone only redness remained, patient reports itching improved.  By 1604 redness, hives and itching gone.
Mother states 4-5 hours after receiving vaccination she noticed redness around injection site. Patient has been complaining of soreness and pain. Mother states over night redness spread and swelling around site appeared.
1/7/20 circular redness, itching in upper left arm at injection site, not noticed previously.
pt recv vax 17JAN97 & 18JAN97 pt devel hives over entire body;over the next few day the rash became more maculopapular & not blotchy;pt devel oral lesions;
REDNESS & ITCHING STARTED EVENING OF INJECTION. PARENT USED COOL COMPRESS AND MOTRIN FOR COMFORT MEASURES. 10/26/2017 REDNESS AND ITCHING DIMINISHED. 10/27/2017 REDNESS & ITCHING, HEAT AT SITE OF INJECTION INCREASED. PATIENT ADMITS TO SCRATCHING AREA LATE ON THE EVENING OF 10/26/2017. MEASUREMENTS OF REDNESS & SWELLING ARE 110 MM WIDE BY 120 MM LONG. PNP PRESCRIBED AUGMENTIN 875 MG BID FOR 10 DAYS, PREDNISONE 20 MG BID FOR 5 DAYS, BENADRYL 25MG CAPSULES Q 6 HOURS FOR ALLERGIC REACTION.
17years old patient received the Moderna COVID-19 vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17years old patient received the Moderna COVID-19 vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17years old patient received the Moderna COVID-19 vaccine). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17years old patient received the Moderna COVID-19 vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Action taken :not applicable No concomitant and treatment information was provided.
This spontaneous report as received from a nurse practitioner refers to a patient of unknown demographics. The concurrent condition, medical history and concomitant medications was not reported. On 27-MAY-2015, the patient was vaccinated with tone dose of VARIVAX (Merck). No adverse event was reported. Additional information has been requested.
Muscle aches; Chills; Fever little over 100; This is a spontaneous report from a contactable nurse. A female patient of an unspecified age received bnt162b2 (BNT162B2, lot number and expiry date were not reported), via an unspecified route of administration on Dec2020 at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced muscle aches, chills and fever little over 100 on Dec2020 with outcome of unknown.    Information on the lot/batch number has been requested.
Chills, low grade fever, joint muscle pain, headache, extreme fatigue   Lasted approximately 24 hours. Next day felt normal